Background: Pathogenic yeasts resistance to current drugs emphasizes the need for new, safe,\nand cost-effective drugs. Also, new inhibitors are needed to control the effects of enzymes that are\nimplicated in metabolic dysfunctions such as cancer, obesity, and epilepsy. Methods: The anti-yeast extract\nfrom Terminalia mantaly (Combretaceae) was fractionated and the structures of the isolated compounds\nestablished by means of spectroscopic analysis and comparison with literature data. Activity was assessed\nagainst Candida albicans, C. parapsilosis and C. krusei using the microdilution method, and against four\nenzymes of metabolic significance: glucose-6-phosphate dehydrogenase, human erythrocyte carbonic\nanhydrase I and II, and glutathione S-transferase. Results: Seven compounds, 3,3-di-O-methylellagic\nacid 4-O-�±-rhamnopyranoside; 3-O-methylellagic acid; arjungenin or 2,3,19,23-tetrahydroxyolean-12-en-\n28-o�¯c acid; arjunglucoside or 2,3,19,23-tetrahydroxyolean-12-en-28-o�¯c acid glucopyranoside;\n2�±,3�±,24-trihydroxyolean-11,13(18)-dien-28-o�¯c acid; stigmasterol; and stigmasterol 3-O-�²-dglucopyranoside\nwere isolated from the extract. Among those, 3,3-di-O-methylellagic acid\n4-O-�±-rhamnopyranoside, 3-O-methylellagic acid, and arjunglucoside showed anti-yeast activity\ncomparable to that of reference fluconazole with minimal inhibitory concentrations (MIC) below\n32 �¼g/mL. Besides, Arjunglucoside potently inhibited the tested enzymes with 50% inhibitory\nconcentrations (IC50) below 4 �¼M and inhibitory constant (Ki) <3 �¼M. Conclusions: The results\nachieved indicate that further SAR studies will likely identify potent hit derivatives that should\nsubsequently enter the drug development pipeline.
Loading....